Dr. Loeffler's appointment comes as Helix prepares to enter a more execution-focused phase of clinical development, with multiple programs approaching key regulatory and clinical milestones. As CMO, ...
TEL AVIV, Israel, May 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...
Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with limited treatment options, today announced the appointment of Mark Forman, M.D., Ph.D. as ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...
The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) ...
The publication serves as an industry roadmap while validating SL Science’s overarching business strategy and research direction. Glioblastoma remains notoriously difficult to treat because tumors ...
Good afternoon, and thank you for joining us today for BioAge Labs R&D Day. I'm Chris Patil, VP of Media at BioAge. Before we begin, I would like to remind everyone that during this call, we will be ...
To be successful in today's dynamic and increasingly cost-conscious healthcare environment requires medical device companies to fundamentally change the way they think about their products. Companies ...
Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...
Great. Good morning, global investors. Thank you for joining CStone Pharmaceuticals' ESMO Data Review Conference Call. The call is going to be mainly focused on the CF2009 data readouts at the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results